Wave Life Sciences Ltd (NASDAQ: WVE)’s Outlook Shocks Bears.

In the last trading session, 2.04 million shares of the Wave Life Sciences Ltd (NASDAQ:WVE) were traded, and its beta was -1.09. Most recently the company’s share price was $11.23, and it changed around $1.18 or 11.74% from the last close, which brings the market valuation of the company to $1.71B. WVE currently trades at a discount to its 52-week high of $16.74, offering almost -49.07% off that amount. The share price’s 52-week low was $4.25, which indicates that the current value has risen by an impressive 62.15% since then.

Wave Life Sciences Ltd stock received a consensus recommendation rating of Buy, based on a mean score of 1.22. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended WVE as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Wave Life Sciences Ltd is expected to report earnings per share of -0.26 for the current quarter.

Wave Life Sciences Ltd (NASDAQ:WVE) trade information

Instantly WVE has showed a green trend with a performance of 11.74% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 11.71 on recent trading dayincreased the stock’s daily price by 4.1%. The company’s shares are currently down -9.22% year-to-date, but still up 8.40% over the last five days. On the other hand, Wave Life Sciences Ltd (NASDAQ:WVE) is -2.94% down in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $22, which translates to bulls needing to increase their stock price by 48.95% from its current value. Analyst projections state that WVE is forecast to be at a low of $15 and a high of $36.

Wave Life Sciences Ltd (WVE) estimates and forecasts

The year-over-year growth rate is expected to be -29.42%, down from the previous year.

Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 14.1M in revenue for the current quarter. 5 analysts expect Wave Life Sciences Ltd to make 18.7M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 12.54M and 19.69M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 12.44%. Forecasts for the next quarter put sales growth at -5.05%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 36.03%. Wave Life Sciences Ltd earnings are expected to increase by -52.00% in 2025, but the outlook is negative -3.53% per year for the next five years.

WVE Dividends

Wave Life Sciences Ltd’s next quarterly earnings report is expected to be released in April.

MAVERICK CAPITAL LTD, with 5.9211% or 7.67 million shares worth $38.27 million as of 2024-06-30, holds the second largest percentage of outstanding shares.

iShares Russell 2000 ETF and Primecap Odyssey Aggressive Growth Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.48 shares worth $27.82 million, making up 1.62% of all outstanding shares. On the other hand, Primecap Odyssey Aggressive Growth Fund held roughly 2.45 shares worth around $27.54 million, which represents about 1.61% of the total shares outstanding.